Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab

Date Issued
2019
Author(s)
Villalobos, Matthias
Czapiewski, Piotr
Reinmuth, Niels
Fischer, Jürgen
Kortsik, Cornelius
Serke, Monika
Wolf, Martin
Neuser, Petra
Reuss, Alexander
Schnabel, Philipp
DOI
10.3892/ol.2019.10153